Risky Business: Breast Cancer Risk Factors and What We Know About Them
A look at recent research on determining breast cancer risk, the impact of lifestyle changes on cancer risk, and why screening is important.
Progress Against Cancer
A look at recent research on determining breast cancer risk, the impact of lifestyle changes on cancer risk, and why screening is important.
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in certain adult and pediatric patients 1 year and older. The U.S. Food and...
COVID vaccines may improve immunotherapy effects, and a drug combination reduces the risk for death in bladder cancer.
In October 2025, AACR's journals editors highlighted studies on the anticancer function of an Alzheimer’s-related protein, small-molecule-drug conjugates, and more.
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory or recurrent multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf...
The AACR Conference on the Science of Cancer Health Disparities explored the field's evolving landscape, including funding and and long-term impact.
Frank McCormick, PhD, FAACR, reflected on a career chasing the notorious RAS oncogene that earned him the inaugural Stephenson Global Prize.
The psychological toll of cancer can have an impact on patients’ mental health and put them at an increased risk of harm.
Older people with multiple myeloma can receive a less toxic drug regimen, and the FDA approves an immunotherapy for people with high-risk skin cancer.
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for use after...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More